Cargando…
Proposed lead molecules against Hemagglutinin of avian influenza virus (H5N1)
Human infection with avian influenza H5N1 is an emerging infectious disease characterized by respiratory symptoms and a high fatality rate. Hemagglutinin and neuraminidase are the two surface proteins responsible for infection by influenza virus. Till date, neuraminidase has been the major target fo...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Biomedical Informatics Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2258429/ https://www.ncbi.nlm.nih.gov/pubmed/18317572 |
_version_ | 1782151343243264000 |
---|---|
author | Nandi, Tannistha |
author_facet | Nandi, Tannistha |
author_sort | Nandi, Tannistha |
collection | PubMed |
description | Human infection with avian influenza H5N1 is an emerging infectious disease characterized by respiratory symptoms and a high fatality rate. Hemagglutinin and neuraminidase are the two surface proteins responsible for infection by influenza virus. Till date, neuraminidase has been the major target for antiviral drugs. In the present study we chose hemagglutinin protein as it mediates the binding of the virus to target cells through sialic acid residues on the host cell-surface. Hemagglutinin of H5 avian influenza (PDB ID: 1JSN) was used as the receptor protein. Ligands were generated by structure-based de novo approach and virtual screening of ZINC database. A total of 11,104 conformers were generated and docked into the receptor binding site using ‘High Throughput Virtual Screening’. We proposed potential lead molecules against the receptor binding site of hemagglutinin based on the results obtained from in silico docking and hydrogen bond interaction between the ligand and the 1JSN protein molecule. We found sialic acid derivative 1 to be the lead molecules amongst the ligands generated by structure based de novo approach. However the molecules obtained from ZINC database were showing better docking scores as well as conserved hydrogen bond interactions. Thus we proposed ZINC00487720 and ZINC00046810 as potential lead molecules that could be used as an inhibitor to the receptor binding site of hemagglutinin. They could now be studied in vivo to validate the in silico results. |
format | Text |
id | pubmed-2258429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Biomedical Informatics Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-22584292008-03-03 Proposed lead molecules against Hemagglutinin of avian influenza virus (H5N1) Nandi, Tannistha Bioinformation Hypothesis Human infection with avian influenza H5N1 is an emerging infectious disease characterized by respiratory symptoms and a high fatality rate. Hemagglutinin and neuraminidase are the two surface proteins responsible for infection by influenza virus. Till date, neuraminidase has been the major target for antiviral drugs. In the present study we chose hemagglutinin protein as it mediates the binding of the virus to target cells through sialic acid residues on the host cell-surface. Hemagglutinin of H5 avian influenza (PDB ID: 1JSN) was used as the receptor protein. Ligands were generated by structure-based de novo approach and virtual screening of ZINC database. A total of 11,104 conformers were generated and docked into the receptor binding site using ‘High Throughput Virtual Screening’. We proposed potential lead molecules against the receptor binding site of hemagglutinin based on the results obtained from in silico docking and hydrogen bond interaction between the ligand and the 1JSN protein molecule. We found sialic acid derivative 1 to be the lead molecules amongst the ligands generated by structure based de novo approach. However the molecules obtained from ZINC database were showing better docking scores as well as conserved hydrogen bond interactions. Thus we proposed ZINC00487720 and ZINC00046810 as potential lead molecules that could be used as an inhibitor to the receptor binding site of hemagglutinin. They could now be studied in vivo to validate the in silico results. Biomedical Informatics Publishing Group 2008-01-27 /pmc/articles/PMC2258429/ /pubmed/18317572 Text en © 2008 Biomedical Informatics Publishing Group This is an open-access article, which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes, provided the original author and source are credited. |
spellingShingle | Hypothesis Nandi, Tannistha Proposed lead molecules against Hemagglutinin of avian influenza virus (H5N1) |
title | Proposed lead molecules against Hemagglutinin of avian influenza virus (H5N1) |
title_full | Proposed lead molecules against Hemagglutinin of avian influenza virus (H5N1) |
title_fullStr | Proposed lead molecules against Hemagglutinin of avian influenza virus (H5N1) |
title_full_unstemmed | Proposed lead molecules against Hemagglutinin of avian influenza virus (H5N1) |
title_short | Proposed lead molecules against Hemagglutinin of avian influenza virus (H5N1) |
title_sort | proposed lead molecules against hemagglutinin of avian influenza virus (h5n1) |
topic | Hypothesis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2258429/ https://www.ncbi.nlm.nih.gov/pubmed/18317572 |
work_keys_str_mv | AT nanditannistha proposedleadmoleculesagainsthemagglutininofavianinfluenzavirush5n1 |